Systemic antibacterial agents

Comprehensive Dermatologic Drug Therapy: Expert Consult - Online and Print

Volumn , Issue , 2012, Pages 61-97

  Kim, Susun ^a,b   Michaels, Brent D ^c   Kim, Grace K ^c   Del Rosso, James Q ^a,b,c  

^a TOURO UNIVERSITY NEVADA   (United States)

^b Las Vegas Skin & Cancer Clinics Ltd   (United States)

^c VALLEY HOSPITAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85135386914     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4377-2003-7.00008-X     Document Type: Chapter

References (549)

1. Leyden JJ, Del Rosso JQ, Webster GF Clinical considerations in the treatment of acne vulgaris and other inflammatory skin disorders: focus on antibiotic resistance. Dermatol Clin 2009, 27(1):1-15.
2. Webster G, Del Rosso JQ Antiinflammatory activity of tetracyclines. Dermatol Clin 2007, 25(2):133-135.
3. Bhatia N Use of antibiotics for noninfectious dermatologic disorders. Dermatol Clin 2009, 27(1):85-89.
4. Del Rosso JQ, Leyden JJ, Thiboutot D, et al. Antibiotic use in acne vulgaris and rosacea: clinical considerations and resistance issues of significance to dermatologists. Cutis 2008, 82(suppl 2[ii]):5-12.
5. Del Rosso JQ, Leyden JJ Status report on antibiotic resistance: implications for the dermatologist. Dermatol Clin 2007, 25(2):127-132.
6. Elston D How to handle a CA-MRSA outbreak. Dermatol Clin 2009, 27(1):43-48.
7. Elston D Methicillin-sensitive and methicillin-resistant Staphylococcus aureus: management principles and selection of antibiotic therapy. Dermatol Clin 2007, 25(2):157-164.
8. Del Rosso JQ, Bhambri S, Kim G Use of oral doxycycline for community-acquired methicillin-resistant Staphylococcus aureus (CA-MRSA) Infections. J Clin Aesthet Dermatol 2009, 2(4):45-50.
9. Knowles SR, Shear NH Recognition and management of severe cutaneous drug reactions. Dermatol Clin 2007, 25(2):245-253.
10. Kadurina M, Bocheva G, Tonev S Penicillin and semisynthetic penicillins in dermatology. Clin Dermatol 2003, 21(1):12-23.
11. Leachman SA, Reed BR The use of dermatologic drugs in pregnancy and lactation. Dermatol Clin 2006, 24(2):167-197.
12. Drug facts and comparisons: anti-infective agents October 2005, Published by, Wolters Kluwer. On-line ed.
13. Duvanel T, Merot Y, Saurat JH Prophylactic antibiotics in erysipelas. Lancet 1985, 1:1401.
14. Calguneri M, Ertenli I, Kiraz S, et al. Effect of prophylactic benzanthine penicillin on mucocutaneous symptoms of Behcet's disease. Dermatology 1996, 192:125-128.
15. Naldi L, Chalmers RJ Psoriasis. Evidenced-Based Dermatology 2008, 183. Blackwell Publishers, Malden, Massachusetts. 2nd ed. H. Williams, M. Bigby, T. Diepgen, A. Herxheimer, L. Naldi, B. Rzany (Eds.).
16. Vincent F, Ross JB, Dalton M, et al. A therapeutic trial of the use of penicillin V or erythromycin with or without rifampin in the treatment of psoriasis. J Am Acad Dermatol 1992, 26:458-461.
17. Torres MJ, Blanca M The complex clinical picture of lactam hypersensitivity: penicillins, cephalosporins, monobactams, carbapenems, and clavams. Medical Clinics of North America 2010, 94(4):805-820.
18. Romano A, Gueant-Rodriguez RM, Viola M, et al. Cross-reactivity and tolerability of cephalosporins in patients with immediate hypersensitivity to penicillins. Ann Intern Med 2004, 141(1):16-22.
19. Romano A, Blanca M, Torres MJ, et al. Diagnosis of nonimmediate reactions to beta-lactam antibiotics. Allergy 2004, 59:1153-1160.
20. Romano A, Blanca M, Mayorga C, et al. Immediate hypersensitivity to penicillins. Studies on Italian subjects. Allergy 1997, 52:89-93.
21. Ponvert C, Le Clainche L, de Blic K, et al. Allergy to beta-lactam antibiotics in children. Pediatrics 1999, 104:45.
22. Assem ES, Vickers MR Test for penicillin allergy in man. II. The immunologic cross-reaction between penicillins and cephalosporins. Immunology 1974, 27:255-269.
23. Herman R, Jick H Cutaneous reaction rates to penicillins: oral versus parenteral. Cutis 1979, 24:232-234.
24. Mitropoulos IF, Rotschafer JC, Rodvold KA Adverse events associated with the use of oral cephalosporins /cephems. Diagnostic Microbiology and Infectious Disease 2007, 57:67S-76S.
25. AllerQuest Pre-Pen® Update http://www.allerquest.com.
26. Alanis A, Weinstein AJ Adverse reactions associated with the use of oral penicillins and cephalosporins. Med Clin North Am 1983, 67:113-129.
27. Cohen PR, Daniel CR, Scher RK Systemic drugs. Nails: therapy, diagnosis, surgery 2005, 177-194. Elsevier/Saunders, Philadelphia. 3rd ed. R.K. Scher, C.R. Daniel, A. Tosti (Eds.).
28. Brown SJ, Desmond PV Hepatotoxicity of antimicrobial agents. Semin Liver Dis 2002, 22(2):157-167.
29. Neu HC The new beta-lactamase-stable cephalosporins. Ann Intern Med 1982, 97:408-419.
30. Del Rosso JQ Cephalosporins in dermatology. Clin Dermatol 2003, 21(1):24-32.
31. Epstein ME, Amodio-Groton MA, Sadick NA Antimicrobial agents for the dermatologist. I. Beta-lactam antibiotics and related compounds. J Am Acad Dermatol 1997, 37:149-165.
32. Martin SI, Kaye KM Beta-lactam antibiotics: newer formulations and newer agents. Infect Dis Clin N Am 2004, 18:603-619.
33. Forest Laboratories Forest announces FDA approval of Teflaro (ceftaroline fosamil) for the treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infection Press release accessed at, on October 29, 2010. http://www.frx.com.
34. Steed ME, Rybak MJ Ceftaroline: a new cephalosporin with activity against resistant Gram-positive pathogens. Pharmacotherapy 2010, 30(4):375-389.
35. Juan C, Zamorano L, Perez JL, et al. Activity of a new antipseudomonal cephalosporin, CXA-101 (FR264205), against carbapenem-resistant and multidrug-resistant Pseudomonas aeruginosa clinical strains. Antimicrobial Agents and Chemotherapy 2010, 54(2):846-851.
36. Fassberder M, Lode H, Schaberg T, et al. Pharmacokinetics of new oral cephalosporins, including a new carbacephem. Clin Infect Dis 1993, 16:646-653.
37. Gustaferro CA, Steckelberg JM Cephalosporin anti-microbial agents and related compounds. Mayo Clin Proc 1991, 66:1064-1073.
38. Ceftaroline fosamil (Teflaro), Package insert, Forest Laboratories, New York, New York, October 2010.
39. Nadelman RB, Luger SW, Frank E, et al. Comparison of cefuroxime axetil and doxycycline in the treatment of early Lyme disease. Ann Intern Med 1992, 117:273-280.
40. Parish LC, Jungkind DL Systemic antimicrobial therapy for skin and skin structure infections. Comparison of fleroxacin and ceftazidime. Am J Med 1993, 94(Suppl 3A):166-173.
41. Corey GR, Wilcox M, Talbot GH Integrated analysis of CANVAS 1 and 2: phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection. Clin Infect Dis 2010, 51(6):641-650.
42. Chahine EB Ceftobiprole: farewell or just a delay?. Am J Health Syst Pharm 2010, 67:981.
43. Noel GJ, Strauss RS, Amsler K, et al. Results of a double-blind, randomized trial of ceftobiprole treatment of complicated skin and skin structure infections caused by Gram-positive bacteria. Antimicrobial Agents and Chemotherapy 2008, 52(1):37-44.
44. Dauner DG, Nelson RE, Taketa DC Ceftobiprole: a novel, broad spectrum cephalosporin with activity against methicillin-resistant Staphylococcus aureus. Am J Health Syst Pharm 2010, 67(12):983-993.
45. Lopez AJ, O'Keefe P, Mornssey M, et al. Ceftriaxone-induced cholelithiasis. Ann Intern Med 1991, 115:712-714.
46. Levine BB Antigenicity and cross reactivity of penicillins and cephalosporins. J Infect Dis 1973, 128:364-366.
47. Pichichero ME A review of evidence supporting the American Academy of Pediatrics recommendation for prescribing cephalosporin antibiotics for penicillin-allergic patients. Pediatrics 2005, 115(4):1048-1057.
48. Apter AJ, Kinman JL, Bilker WB, et al. Is there a cross-reactivity between penicillins and cephalosporins?. The American Journal of Medicine 2006, 119(4):354.e11-354.e20.
49. Kelkar PS, Li JTC Cephalosporin Allergy. The New England Journal of Medicine 2001, 345(11):804-809.
50. Reynolds RD, Grammer LC, Kelsey DK Cefaclor and serum sickness-like reactions. JAMA 1996, 276:950-951.
51. Garratty G Drug-induced immune hemolytic anemia. Hematology 2009, 1:73.
52. Sang N, Kammer RB Hematologic complications associated with beta-lactam antibiotics. Rev Infect Dis 1983, 5:380-393.
53. Fass RJ, Perkins RL, Saslaw S Cephalexin-a new oral cephalosporin: clinical evaluation in sixty-three patients. Am J Med Sci 1970, 259:187.
54. Buenting MK, Wold JS, Israel JS, et al. Disulfiram-like reactions to b-lactams (letter). JAMA 1981, 245:2027.
55. Aria N, Kauffman CL Important drug interactions and reactions in dermatology. Dermatol Clin 2003, 21:207-215.
56. Barranco VP Clinically significant drug interaction in dermatology. J Am Acad Dermatol 1998, 38:599-612.
57. Martin SI, Kaye KM Beta-lactam antibiotics: newer formulations and newer agents. Infect Dis Clin N Am 2004, 18:603-619.
58. Lee N, Yuen KY, Kumana CR Clinical role of beta-lactam/beta-lactamase inhibitor combinations. Drugs 2003, 63(14):1511-1524.
59. Sensakovic JW, Smith LG Beta-lactamase inhibitor combinations. Med Clin North Am 1995, 79:695-704.
60. Maddux MS Effects of beta-lactamase-mediated antimicrobial resistance: the role of beta-lactamase inhibitors. Pharmacotherapy 1991, 11:40S-50S.
61. Stein GE, Gurwith MJ Amoxicillin-potassium clavulanate, a beta-lactamase-resistant antibiotic combination. Clin Pharm 1984, 3:591-599.
62. Staniforth DH, Lilystone KJ, Jackson D Effect of food on the bioavailability and tolerance of clavulanic acid/amoxicillin combination. J Antimicrob Chemother 1982, 10:131-139.
63. Goldstein EJC, Reinhardt JF, Murray PM, et al. Outpatient therapy of bite wounds: demographic data, bacteriology and a prospective, randomized trial of amoxicillin-clavulanic acid versus penicillin 6 dicloxacillin. Int J Dermatol 1987, 26:123-131.
64. Iskender S The role of b-lactam/b-lactamase inhibitor combinations in surgical infections. Surg Infec 2001, 2(1):23-32.
65. Brown CH, Natelson EA, Bradshaw MW, et al. Study of the effects of ticarcillin on blood coagulation and platelet function. Antimicrob Agents Chemother 1975, 7:652-657.
66. Bryson HM, Brogden RN Piperacillin/tazobactam. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential. Drugs 1994, 47:506-535.
67. Itokazu GS, Danziger LH Ampicillin-sulbactam and ticarcillin-clavulanic acid: a comparison of their in vitro activity and review of their clinical efficacy. Pharmacotherapy 1991, 11:382-414.
68. Staniforth DH, Jackson D, Clarke HL, et al. Amoxicillin/clavulanic acid: the effect of probenecid. J Antimicrob Chemother 1983, 12:273.
69. Ganes D, Batra V, Faulkner K, et al. Effect of probenecid on the pharmacokinetics of piperacillin and tazobactam in healthy volunteers. Proceedings of the Sixth Annual Meeting and Exposition, American Associated of Pharmaceutical Scientists, Washington, DC 1991; Abstract PPDM8293. Pharmaceutical Research 8, S299.
70. Hellinger WC, Brewer NS Imipenem. Mayo Clin Proc 1991, 66:1074-1081.
71. Zhanel GG, Johanson C, Embil JM, et al. Ertapenem: review of a new carbapenem. Expert Rev Anti-infect Ther 2005, 3(1):23-39.
72. Jones RN Review of the in vitro spectrum of activity of imipenem. Am J Med 1985, 78:22-32.
73. Norrby SR Carbapenems. Med Clin North Am 1995, 79:745-759.
74. Wexler HM In vitro activity of ertapenem: review of recent studies. J Antimicrob Chemother 2004, 53(Suppl 2):11-21.
75. Fass RJ, Freimer EH, McCloskey RV Treatment of skin and soft tissue infections with imipenem/cilastatin. Am J Med 1985, 78:110-112.
76. Saxon A, Beall GN, Rohr AS, et al. Immediate hypersensitivity reactions to beta-lactam antibiotics. UCLA Conference. Ann Intern Med 1987, 107:204-215.
77. Prescott WA, DePestel DD, Ellis JJ, et al. Incidence of carbapenem-associated allergic-type reactions among patients with versus patients without a reported penicillin allergy. Clin Infect Dis 2004, 38(8):1102-1107.
78. Brewer NS, Hellinger WC The monobactams. Mayo Clin Proc 1991, 66:1152-1157.
79. Neu HC Aztreonam: the first monobactam. Med Clin North Am 1988, 72:555-566.
80. Scully BE, Henry SA Clinical experience with aztreonam in the treatment of Gram-negative bacteremia. Rev Infect Dis 1985, 7(Suppl 4):789-793.
81. Anonymous Aztreonam. AHFS Drug Information 95. Am Soc Health Syst Pharm 1995, 170-178.
82. Buesing MA, Jorgersen JH In vitro activity of aztreonam in combination with newer b-lactams and amikacin against multiply resistant bacilli. Antimicrob Agents Chemother 1984, 25:283-285.
83. Finch RG, Eliopoulos GM Safety and efficacy of glycopeptide antibiotics. J Antimicro Chemother 2005, 55(Suppl 2):5-13.
84. Smith TL, Pearson ML, Wilcox KR, et al. Emergence of vancomycin resistance in Staphylococcus aureus. N Engl J Med 1999, 340:493-501.
85. Charneski L, Patel PN, Sym D Telavancin: a novel lipoglycopeptide antibiotic. Ann Pharmacother 2009, 43(5):928-938.
86. Hull MW, Beck PL Clostridium difficile-associated colitis. Can Fam Physician 2004, 50:1536-1540.
87. Chen C-J, Huang YC, Chiu CH, et al. Clinical features and genotyping analysis of community-acquired methicillin-resistant Staphylococcus aureus infections in Taiwanese children. Pediatr Infect Dis J 2005, 24:40-45.
88. Curcio D Resistant pathogen-associated skin and skin-structure infections: antibiotic options. Exp Rev Anti-Infect Ther 2010, 8(9):1019-1036.
89. Barton E, MacGowan A Future treatment options for Gram-positive infections - looking ahead. Clin Microbiol Infect 2009, 15(Suppl 6):17-25.
90. Bernstein EF, Schuster M Linear IgA bullous dermatosis associated with vancomycin. Ann Intern Med 1998, 129(6):508-509.
91. Neughebauer BI, Negron G, Pelton S, et al. Bullous skin disease: an unusual allergic reaction to vancomycin. Am J Med Sci 2002, 323(5):273-278.
92. Hughes AP, Callen JP Drug-induced linear IgA bullous dermatosis mimicking toxic epidermal necrolysis. Dermatology 2001, 202(2):138-139.
93. Waldman MA, Black DR, Callen JP Vancomycin-induced linear IgA bullous dermatosis presenting as toxic epidermal necrolysis. Clin Exp Dermatol 2004, 29(6):633-636.
94. Khan I, Hughes R, Curran S, et al. Drug-associated linear IgA disease mimicking toxic epidermal necrolysis. Clin Exp Dermatol 2009, 34(6):715-717.
95. Coelho S, Tellechea O, Rhea JP, et al. Vancomycin-associated linear IgA bullous dermatosis mimicking toxic epidermal necrolysis. Int J Dermatol 2006, 45(8):995-996.
96. Billet SE, Kortuem KR, Gibson LE, et al. A morbilliform variant of vancomycin-induced linear IgA bullous dermatosis. Arch Dermatol 2008, 144(6):774-778.
97. Palmer RA, Ogg G, Allen J, et al. Vancomycin-induced linear IgA disease with autoantibodies to BP180 and LAD285. Br J Dermatol 2001, 145(5):816-820.
98. Bahal N, Nahata MC The new macrolide antibiotics: azithromycin, clarithromycin, dirithromycin and roxithromycin. Ann Pharmacother 1992, 26:46-55.
99. Brogden RN, Peters DH Dirithromycin: a review of its antimicrobial activity, pharmacokinetic properties and therapeutic efficacy. Drugs 1994, 48:599-616.
100. Schlossberg D Azithromycin and clarithromycin. Med Clin North Am 1995, 79:803-815.
101. Borszcz PD, Befus D, Moqbel R, et al. Effects of clarithromycin on inflammatory cell mediator release and survival. Chemotherapy 2005, 51(4):206-210. (Epub 2005 Jul 6).
102. Kanai K, Asano K, Hisamitsu T, et al. Suppression of matrix metalloproteinase-9 production from neutrophils by a macrolide antibiotic, roxithromycin, in vitro. Mediators Inflamm 2004, 13(5-6):313-319.
103. Jain A, Sangal L, Basal E, et al. Anti-inflammatory effects of erythromycin and tetracycline on Propionibacterium acnes induced production of chemotactic factors and reactive oxygen species by human neutrophils. Dermatol Online J 2002, 8(2):2.
104. Piscitelli SC, Danziger LH, Rodvold KA Clarithromycin and azithromycin: new macrolide antibiotics. Clin Pharm 1992, 11:137-152.
105. Del Rosso JQ Oral antibiotic drug interactions of clinical significance to dermatologists. Dermatol Clin 2009, 27(1):91-94.
106. O'Mara NB New drug: telithromycin (Ketek). Prescriber's Letter 2004, 11:200606.
107. Scheinfeld N Telithromycin: a brief review of a new ketolide antibiotic. J Drugs Dermatol 2004, 3:409-413.
108. Soreth J, Cox E, Kweder S, et al. Ketek - the FDA perspective. N Engl J Med 2007, 356(16):1675-1676.
109. Ross DB The FDA and the case of Ketek. N Engl J Med 2007, 356(16):1601-1604.
110. Graham DJ Telithromycin and acute liver failure. N Engl J Med 2006, 355(21):2260-2261.
111. Rafle S, MacDougall C, James CL Cethromycin: a promising new ketolide antibiotic for respiratory infections. Pharmacotherapy 2010, 30(3):290-303.
112. Reinert RR Clinical efficacy of ketolides in the treatment of respiratory tract infections. The Journal of Antimicrobial Chemotherapy 2004, 53(6):918-927.
113. McGhee P, Clark C, Kosowska-Shick KM, et al. In vitro activity of CEM-101 against streptococcus pneumonia and streptococcus pyogenes with defined macrolide resistance mechanisms. Antimicrob Agents Chemother 2010, 54(1):230-238.
114. Sturgill MG, Rapp RP Clarithromycin: a review of a new macrolide antibiotic with improved microbiologic spectrum and favorable pharmacokinetic and adverse effect profiles. Ann Pharmacother 1992, 26:1099-1108.
115. Hardy DJ, Swanson RN, Rode RA, et al. Enhancement of the in vitro and in vivo activities of clarithromycin against Haemophilus influenzae by 14-hydroxy-clarithromycin, its major metabolite in humans. Antimicrob Agents Chemother 1990, 34:1407-1413.
116. Scheinfeld NS, Tutrone WD, Torres O, et al. Macrolides in dermatology. Clin Dermatol 2003, 21(1):40-49.
117. Kitzis MD, Goldstein FW, Miegi M, et al. In vitro activity of azithromycin against various Gram-negative bacilli and anaerobic bacteria. J Antimicrob Chemother 1990, 25(Suppl A):15-18.
118. Gelber RH, Sui P, Tsang M, et al. Activities of various macrolide antibiotics against Mycobacterium leprae infection in mice. Antimicrob Agents Chemother 1991, 35:760-763.
119. Perronne C, Gikas A, Truffot-Pernot C, et al. Activities of sparfloxacin, azithromycin, temafloxacin and rifapentine compared with that of clarithromycin against multiplication of Mycobacterium avium complex within human macrophages. Antimicrob Agents Chemother 1991, 35:1356-1359.
120. Benson CA, Ellner JJ Mycobacterium avium complex infection and AIDS: advances in theory and practice. Clin Infect Dis 1993, 17:7-20.
121. Fernandez-Martin J, Leport C, Moriat P, et al. Pyrimethamine-clarithromycin combination for therapy of acute toxoplasma encephalitis in patients with AIDS. Antimicrob Agents Chemother 1991, 35:2049-2052.
122. Wynn RF, Leen CLS, Brettle RP Azithromycin for cerebral toxoplasmosis in AIDS (letter). Lancet 1993, 341:243-244.
123. Peterson WL, Graham DY, Marshall B, et al. Clarithromycin as monotherapy for eradication of Helicobacter pylori: a randomized, double-blind trial. Am J Gastroenterol 1993, 88:1860-1864.
124. Lassus A Comparative studies of azithromycin in skin and soft tissue infections and sexually transmitted infections by Neisseria and Chlamydia species. J Antimicrob Chemother 1990, 25(Suppl A):115-121.
125. Northcutt VJ, Craft JC, Pichotta P. Safety and efficacy of clarithromycin (C) compared to erythromycin (E) in the treatment (tx) of bacterial skin or skin structure infections (SSSls) (abstract 1339). In ProGram and Abstracts of the 30th Interscience Conference on Antimicrob Agents and Chemother, Atlanta 1990.
126. Parish LC The Clarithromycin Study Group. Clarithromycin in the treatment of skin and skin structure infections: two multicenter clinical studies. Int J Dermatol 1993, 32:528-532.
127. Franck N, Cabie A, Villette B, et al. Treatment of Mycobacterium chelonae induced skin infection with clarithromycin. J Am Acad Dermatol 1993, 28:1019-1020.
128. Del Rosso JQ, Kim G Optimizing use of oral antibiotics in acne vulgaris. Dermatol Clin 2009, 27(1):33-42.
129. Amin K, Riddle CC, Aires DJ, et al. Common and alternative oral therapies for acne vulgaris: a review. J Drugs Dermatol 2007, 6(9):873-880.
130. Rafiei R, Yaghoobi R Azithromycin versus tetracycline in the treatment of acne vulgaris. J Drugs Dermatol 2006, 17(14):217-221.
131. Akhyani M, Ehsani AH, Ghiasi M, et al. Comparison of efficacy of azithromycin vs. doxycycline in the treatment of rosacea: a randomized open clinical trial. Int J Dermatol 2008, 47(3):284-288.
132. Modi S, Harding M, Rosen T Azithromycin as an alternative rosacea therapy when tetracyclines prove problematic. J Drugs Dermatol 2008, 7(9):898-899.
133. Gupta AK Perioral dermatitis. Evidenced-Based Dermatology 2008, 111-116. Blackwell Publishers, Malden, Massachusetts. 2nd ed. H. Williams, M. Bigby, T. Diepgen, A. Herxheimer, L. Naldi, B. Rzany (Eds.).
134. Sharma PK, Yadav TP, Gautam RK, et al. Erythromycin in pityriasis rosea: a double-blind, placebo-controlled clinical trial. J Am Acad Dermatol 2000, 42:241-244.
135. Bigby M A remarkable result of a double-masked placebo-controlled trial of erythromycin in the treatment of pityriasis rosea. Arch Dermatol 2000, 136:775-776.
136. Periti P, Mazzei T, Mini E, et al. Adverse effects of macrolide antibacterials. Drug Saf. 1993, 9(5):346-364.
137. Luft BJ, Dattwyler RJ, Johnson RC Azithromycin compared with amoxicillin in the treatment of erythema migrans. A double-blind, randomized controlled trial. Ann Intern Med 1996, 124:785-791.
138. Stein GE, Havlichek DH The new macrolide antibiotics: azithromycin and clarithromycin. Postgrad Med 1992, 92:269-280.
139. Guo D, Cai Y, Chai D, et al. The cardiotoxicity of macrolides: a systematic review. Pharmazi.e 2010, 65(9):631-640.
140. Jennett AM, Bali D, Jasti P, et al. Telithromycin and myasthenic crisis. Clin Infect Dis 2006, 43(12):1621-1622.
141. Perrot X, Bernard N, Vial C, et al. Neurology 2006, 67(12):2256-2258.
142. Sorensen HT, Skriver MV, Pedersen L, et al. Risk of infantile hypertrophic pyloric stenosis after maternal postnatal use of macrolides. Scand J Infect Dis 2003, 35(2):104-106.
143. Cooper WO, Griffin MR, Arbogast P, et al. Very early exposure to erythromycin and infantile hypertrophic pyloric stenosis. Arch Pediatr Adolesc Med 2002, 156(7):647-650.
144. Kallen BA, Otterblad-Olausson P, Danielsson BR Is erythromycin therapy teratogenic in humans?. Reprod Toxicol 2005, 20(2):209-214.
145. Goldstein LH, Berlin M, Tsur L, et al. The safety of macrolides during lactation. Breastfeed Med 2009, 4(4):197-200.
146. Einarson A, Phillips E, Mawji F, et al. A prospective controlled multicentre study of clarithromycin in pregnancy. Am J Perinatol 1998, 15(9):523-525.
147. Phillipson A, Sabath LD, Charles D Transplacental passage of erythromycin and clindamycin. N Eng J Med 1973, 288:1219-1220.
148. Kiefer L, Rubin A, McCoy JB, et al. The placental transfer of erythromycin. Am J Obstet Gynecol 1955, 69:174-177.
149. McCormack WM, George H, Donner A, et al. Hepatotoxicity of erythromycin estolate during pregnancy. Antimicrob Agents Chemother 1977, 12:630-635.
150. Kallen BAJ, Olausson PO Maternal drug use in early pregnancy and infant cardiovascular defect. Reprod Toxicol 2003, 17:255-261.
151. Briggs GG, Freeman RK, Yaffe SJ Erythromycin. Drugs in Pregnancy and Lactation 2005, 588-590. Lippincott Williams & Wilkins, Philadelphia. 7th ed. G.G. Briggs, R.K. Freeman, S.J. Yaffe (Eds.).
152. Gollnick H, Cunliffe W, Berson D, et al. Management of acne: a report from a global alliance to improve outcomes in acne. J Am Acad Dermatol 2003, 49:S1-S38.
153. Van Rosensteil NA, Adam D Macrolide antibacterials: drug interactions of clinical significance. Drug Saf 1995, 13(2):105-122.
154. Zitelli B, Howrie DL, Altman H, et al. Erythromycin-induced drug interactions: an illustrative case and review of the literature. Clin Pediatr 1987, 26(3):117-119.
155. Wroblewski BA, Singer WD, Whyte J. Carbamazepine-erythromycin interaction: case studies and clinical significance. JAMA;255(9):1165-67.
156. Product information Biaxin (R), clarithromycin 1995, Abbott Laboratories, North Chicago, IL.
157. Harris S, Hilligoss D, Colandelo P, et al. Azithromycin and terfenadine: lack of drug interaction. Clin Pharmacol Ther 1995, 58:310-315.
158. Peters DH, Clissold SP Clarithromycin, a review of its antimicrobial activity, pharmacokinetic properties and therapeutic potential. Drugs 1992, 44:117-164.
159. Petty B, Polis M, Haneiwick S, et al. Pharmacokinetic assessment of clarithromycin plus zidovudine in HIV patients (abstract). Presented at the 32nd Interscience Conference on Antimicrob Agents Chemother, Anaheim, CA, 1992.
160. Bolhuis MS, van Altena R, UIges DR, et al. Clarithromycin significantly increases linezolid serum concentrations. Antimicrob Agents Chemother 2010 Sep 13, [Epub ahead of print].
161. Gomes T, Mamdani MM, Juurlink DN Macrolide-induced digoxin-toxicity: a population-based study. Clin Pharmacol Ther 2009, 86(4):383-386.
162. Maxwell DL, Gilmour-White SK, Hall MR Digoxin toxicity due to interaction of digoxin with erythromycin. BMJ 1989, 298(6673):572.
163. Morton MR, Cooper JW Erythromycin-induced digoxin toxicity. DICP 1989, 23(9):668-670.
164. Vergara-Lopez S, Garcia-Garcia JA, Merchante N, et al. Digoxin toxicity secondary to digoxin intestinal metabolism in a patient receiving clarithromycin. Med Clin (Barc) 2004, 123(16):639.
165. Guerriero SE, Ehrenpreis E, Gallagher KL Two cases of clarithromycin-induced digoxin toxicity. Pharmacotherapy 1997, 17(5):1035-1037.
166. Brown BA, Wallace RJ, Griffith DE, et al. Clarithromycin-associated digoxin toxicity in the elderly. Clin Infect Dis 1997, 24(1):92-93.
167. Nenciu LM, Laberge P, Thirion DJ Telithromycin-induced digoxin toxicity and electrocardiographic changes. Pharmacotherapy 2006, 26(6):872-876.
168. Westphal JF Macrolide-induced clinically relevant drug interactions with cytochrome P-450A (CYP) 3A4: an update focused on clarithromycin, azithromycin and dirithromycin. Br J Clin Pharmacol 2000, 50(4):285-295.
169. Amsden GW Macrolides versus azalides: a drug interaction update. Ann Pharmacother 1995, 29(9):906-917.
170. Amacher DE, Schomaker SJ, Retsema JA Comparison of the effects of the new azalide antibiotic azithromycin, and erythromycin estolate on rat liver cytochrome P-450. Antimicrob Agents Chemother 1991, 35:1186-1190.
171. Lindstrom T, Hanssen B, Wrighton S Cytochrome P450 complex formation by dirithromycin and other macrolides in rat and human livers. Antimicrob Agents Chemother 1993, 37:265-269.
172. Suh B, Lorber B Quinolones. Med Clin North Am 1995, 29:869-894.
173. Sable D, Murakawa GJ Quinolones in dermatology. Clin Dermatol 2003, 21(1):56-63.
174. Yee CL, Duffy C, Gerbino PG, et al. Tendon or joint disorders on children after treatment with fluoroquinolones or azithromycin. Pediatr Infect Dis 2002, 21(6):525-529.
175. Weintrub PS Fluoroquinolones in children: use them, but don't abuse them. Journal Watch Pediatrics and Adolescent Medicine August 12, 2002, (accessed on 12/18/2010 at http: //pediatrics.jwatch.org/cgi//content/full/2002/812/1).
176. MacDougall C, Harpe SE, Powell JP, et al. Pseudomonas aeruginosa, Staphylococcus aureus, and fluoroquinolone use. Emerg Infect Dis 2005, 11(8):1197-1204.
177. Pires R, Ardanuy C, Rolo D, et al. Emergence of ciprofloxacin-nonsusceptible Streptococcus pyogenes isolates from healthy children and pediatric patients in Portugal. Antimicrob Agents Chemother 2010, 54(6):2677-2680. [Epub 2010 March 29].
178. Cohen PR, Kurzrock R Community-acquired methicillin-resistant Staphylococcus aureus skin infection: an emerging clinical problem. J Am Acad Dermatol 2004, 50:277-280.
179. Cohen PR Enlarging facial abscess with cellulitis (community-acquired methicillin-resistant Staphylococcus aureus skin infection). (Dermatology Clinic) Clinical Advisor 2005, 8(9):60. 63 and (Dermatology Dx) Cortlandt Forum 2005;18(4):42,45.
180. Fitton A The quinolones. An overview of their pharmacology. Clin Pharmacokinet 1992, 22:1-11.
181. Chin N-X NeuHC. Ciprofloxacin, a quinolone carboxylic acid compound active against aerobic and anaerobic bacteria. Antimicrob Agents Chemother 1984, 25:319-326.
182. Collins CH, Uttley AHC In vitro susceptibility of mycobacteria to ciprofloxacin. J Antimicrob Chemother 1985, 16:575.
183. Hooton TM, Tartaglione TA The role of fluoroquinolones in sexually transmitted diseases. Pharmacotherapy 1993, 13:189-201.
184. Andersson MI, MacGowan AP Development of the quinolones. J Antimicrob Chemother 2003, 51(suppl 1):1-11.
185. Fillastre JP, Leroy A, Moulin B, et al. Pharmacokinetics of quinolones in renal insufficiency. J Antimicrob Chemother 1990, 26(Suppl B):51-60.
186. Smith JW, Nichols RL Comparison of oral fleroxacin with oral amoxicillin/clavulanate for treatment of skin and soft tissue infections. Am J Med 1993, 94:1505-1545.
187. Liu HH Safety profile of the fluoroquinolones: focus on levofloxacin. Drug Saf 2010, 33(5):353-369.
188. Smith CR The adverse effects of fluoroquinolones. J Antimicrob Chemother 1987, 19:709-712.
189. Alghasham AA, Nahata MC Clinical use of fluoroquinolones in children. Ann Pharmacother 2000, 34:347-359.
190. Kim G, Del Rosso JQ The risk of fluoroquinolone-induced tendinopathy and tendon rupture: what does the clinician need to know?. J Clin Aesthet Dermatol 2010, 3(4):49-54.
191. Silva N, Pittman Z, Fernando DJ Tendinopathy with quinolone use: an uncommon adverse effect of a commonly used drug. Eur J Intern Med 2007, 18(7):557.
192. Scheife RT, Cramer WR, Decker EL Photosensitizing potential of ofloxacin. Int J Dermatol 1993, 32:413-416.
193. Lowe NJ, Fakouhi TD, Stern RS, et al. Photoreactions with a fluoroquinolone antimicrobial: evening vs morning dosing. Clin Pharmacol Ther 1994, 56:587-591.
194. LeCleach L, Chosidu O, Berry JP, et al. Blue-black pigmentation of the legs associated with perfloxacin therapy. Arch Dermatol 1995, 131:856-857.
195. Kelesidis T, Fleisher J, Tsiodras S Anaphylactoid reaction considered ciprofloxacin related: a case report and literature review. Clin Ther 2010, 32:515-526.
196. Park-Wyllie LY, Juurlink DN, Kopp A, et al. Outpatient gatifloxacin therapy and dysglycemia in older adults. N Eng J Med 2006, 354(13):1352-1361.
197. Schentag JJ, Watson WA, Nix DE, et al. Time dependent interactions between antacids and quinolone antibiotics. Clin Pharmacol Ther 1988, 43:135.
198. Nix DE, Watson WA, Lener LE, et al. Effects of aluminum and magnesium antacids and ranitidine on the absorption of ciprofloxacin. Clin Pharmacol Ther 1989, 46:700-705.
199. Nakamura H, Ohtsuka T, Enomoto H, et al. Effect of levofloxacin on theophylline clearance during theophylline and clarithromycin combination therapy. Ann Pharmacother 2001, 35:691-693.
200. Kamada AK Possible interaction between ciprofloxacin and warfarin. Drug Intell Clin Pharm 1990, 24:27-28.
201. Jolson HM, Tanner A, Green A, et al. Adverse reaction reporting of interactions between warfarin and fluoroquinolones. Arch Intern Med 1991, 151:1003-1004.
202. Tsankov N, Broshtilova V, Kazandjieva J Tetracyclines in dermatology. Clin Dermatol 2003, 21(1):33-39.
203. Sapadin AN, Fleischmajer R Tetracyclines: Nonantibiotic properties and their clinical implications. JAAD 2006, 54(2):258-265.
204. Webster GF, McGinley KJ, Leyden JJ Inhibition of lipase production in Propionibacterium acnes by subminimal inhibitory concentrations of tetracyclines and erythromycin. Br J Dermatol 1981, 104:453-457.
205. Webster GF, Leyden JJ, McGinley KJ, et al. Suppression of polymorphonuclear leukocyte chemotactic factor production in Propionibacterium acnes by subminimal inhibitory concentrations of tetracyclines and erythromycin. Antimicrob Agents Chemother 1982, 21:770-772.
206. Golub LM, Ramamurthy NS, McNamara TF, et al. Tetracyclines inhibit tissue collagenase activity: a new mechanism in the treatment of periodontal disease. J Periodont Res 1984, 19:651-655.
207. Del Rosso JQ A status report on the use of subantimicrobial-dose doxycycline: a review of the biologic and antimicrobial effects of the tetracyclines. Cutis 2004, 74(2):118-122.
208. Del Rosso JQ Update on rosacea pathogenesis and correlation with medical therapeutic agents. Cutis 2006, 78(2):97-100.
209. Smith EL, al Raddari A, al Ghamdi, et al. Tetracycline phototoxicity. Br J Dermatol 1995, 132(2):316-317.
210. Bjellerup M, Ljunggren B Double-blind cross-over studies on phototoxicity to three tetracycline derivatives in human volunteers. Photodermatol 1987, 4(6):281-287.
211. Frost P, Weinstein GD, Gomez EC Phototoxic potential of minocycline and doxycycline. Arch Dermatol 1972, 105(5):681-683.
212. Cherrill DA, Stote RM, Birge JR, et al. Demeclocycline treatment in the syndrome of inappropriate antidiuretic hormone secretion. Ann Intern Med 1975, 83(5):654-656.
213. Ross JI, Snelling AM, Eady EA, et al. Phenotypic and genotypic characterization of antibiotic-resistant Propionibacterium acnes isolated from acne patients attending dermatology clinics in Europe, the U.S.A., Japan and Australia. Br J Dermatol 2001, 144:339-346.
214. Cooper AJ Systematic review of Propionibacterium acnes resistance to systemic antibiotics. Med J Austral 1998, 169(5):259-261.
215. Eady AE, Cove JH, Layton AM Is antibiotic resistance in cutaneous propionibacteria clinically relevant? Implications of resistance for acne patients and prescribers. Am J Clin Dermatol 2003, 4:813-831.
216. Ross JI, Snelling AM, Carnegie E, et al. Antibiotic-resistant acne: lessons from Europe. Br J Dermatol 2003, 148:467-478.
217. Del Rosso JQ Scientific Panel on Antibiotic Use in Dermatology: Introduction. Cutis 2007, 79(6S):6-8.
218. Tan AW, Tan HH Acne vulgaris: a review of antibiotic therapy. Exp Opin Pharmacother 2005, 6(3):409-418.
219. Thiboutot D, Gollnick H, Bettoli V, et al. New insights into the management of acne: an update from the Global Alliance to improve outcomes in acne group. J Am Acad Dermatol 2009, 60:S1-S50.
220. Del Rosso JQ, Baldwin H, Webster G American Acne & Rosacea Society rosacea management guidelines. J Drugs Dermatol 2008, 7(6):531-533.
221. Pelle MT, Crawford GH, James WD, Rosacea II Therapy. J Am Acad Dermatol 2004, 51(4):499-512.
222. Eady EA, Gloor M, Leyden JJ Propionibacterium acnes resistance: a worldwide problem. Dermatology 2003, 206:54-56.
223. Skidmore R, Kovach R, Walker C, et al. Effects of subantimicrobial-dose doxycycline in the treatment of moderate acne. Arch Dermatol 2003, 139(4):459-464.
224. Preshaw PM, Novak MJ, Mellonig J, et al. Modified-release subantimicrobial dose doxycycline enhances scaling and root planning in subjects with periodontal disease. J Periodontol 2008, 79:440-452.
225. Del Rosso JQ, Webster GF, Jackson M, et al. Two randomized phase III clinical trials evaluating anti-inflammatory dose doxycycline (40-mg doxycycline, USP capsules) administered once daily for treatment of rosacea. J Am Acad Dermatol 2007, 56(5):791-802.
226. Oracea(tm) (doxycycline, USP) Full Prescribing Information 2006, CollaGenex Pharmaceuticals, Inc., Newtown, PA.
227. Leyden JJ, Del Rosso JQ Oral antibiotic therapy for acne vulgaris: pharmacokinetic and pharmacodynamic perspectives. J Clin Aesthet Dermatol 2011, (submitted for publication).
228. Leyden JJ, Kaidbey K, Gans EH The antimicrobial effects in vivo of minocycline, doxycycline and tetracycline in humans. J Dermatol Treat 1996, 7:223-225.
229. Plott RT, Wortzman MS Key bioavailability features of a new extended-release formulation of minocycline hydrochloride tablets. Cutis 2006, 78:6-10.
230. Solodyn(r) (minocycline HCl). Full Prescribing Information, Medicis 2010, The Dermatology Company, Scottsdale, AZ.
231. Stockley IH Antibiotic and anti-infective agent drug interactions. Drug Interactions 1999, 194-197. Pharmaceutical Press, London. 5th ed. I.H. Stockley (Ed.).
232. Ericsson CD, Feldman S, Pickering LK, et al. Influence of subsalicylate bismuth on absorption of doxycycline. JAMA 1982, 247:2266-2267.
233. Leyden JJ Absorption of minocycline hydrochloride and tetracycline hydrochloride: effects of food, milk, and iron. J Am Acad Dermatol 1985, 12:308-312.
234. Bryant SG, Fisher S, Kluge RM Increased frequency of doxycycline side effects. Pharmacotherapy 1987, 7(4):125-129.
235. Kircik LH Doxycycline and minocycline for the management of acne: a review of efficacy and safety with emphasis on clinical implications. J Drugs Dermatol 2010, 9(11):1407-1410.
236. Valean S, Petrescu M, Catinean A, et al. Pill esophagitis. Rom J Gastroenterol 2005, 14(2):159-163.
237. Kadayifci A, Gulsen MT, Koruk M, et al. Doxycycline-induced pill esophagitis. Dis Esophagus 2004, 17(2):168-171.
238. Jarvinen A, Nykanen S, et al. Enteric coating reduces upper gastrointestinal adverse reactions to doxycycline. Clin Drug Invest 1995, 10:323-327.
239. Berger RS A double-blind, multiple-dose, placebo-controlled, cross-over study to compare the incidence of gastrointestinal complaints in healthy subjects given Doryx and Vibramycin. J Clin Pharmacol 1988, 28:367-370.
240. Del Rosso JQ Clinical significance of brand versus generic formulations: focus on oral minocycline. Cutis 2006, 77(3):153-156.
241. Standiford HC Tetracyclines and chloramphenicol. Principles and practice of infectious disease 1995, 306-317. Churchill Livingstone, New York. 4th ed. G.L. Mandell, R.G. Douglas, J.E. Bennett (Eds.).
242. Simonart T, Dramaix M, De Maertelaer V Efficacy of tetracyclines in the treatment of acne vulgaris: a review. Br J Dermatol 2008, 158:208-216.
243. Collier AP, Freeman SR, Dellavalle RP Acne vulgaris. Evidenced-Based Dermatology 2008, 91-97. Blackwell Publishers, Malden, Massachusetts. 2nd ed. H. Williams, M. Bigby, T. Diepgen, A. Herxheimer, L. Naldi, B. Rzany (Eds.).
244. Stewart DM, Torok HM, Weiss JS, Plott RT Dose-ranging efficacy of new once-daily extended-release minocycline for acne vulgaris. Cutis 2006, 78:11-20.
245. Fleischer AB, Dinehart S, Stough D, Plott RT Safety and efficacy of a new extended-release formulation of minocycline. Cutis 2006, 78:21-31.
246. Rebora A Papulopustular rosacea. Evidenced-Based Dermatology 2008, 105-109. Blackwell Publishers, Malden, Massachusetts. 2nd ed. H. Williams, M. Bigby, T. Diepgen, A. Herxheimer, L. Naldi, B. Rzany (Eds.).
247. Quarterman MJ, Johnson DW, Abela DC, et al. Ocular rosacea: signs, symptoms, and tear studies before and after treatment with doxycycline. Arch Dermatol 1997, 133(1):49-54.
248. Fowler JF Combined use of anti-inflammatory dose doxycycline (40 mg doxycycline, USP monohydrate controlled-release capsules) and metronidazole topical gel 1% in the treatment of rosacea. J Drugs Dermatol 2007, 6(6):641-645.
249. Del Rosso JQ, Bruce S, Jarratt M, et al. Efficacy of topical azelaic acid (AzA) gel 15% plus oral doxycycline 40 mg versus metronidazole gel 1% plus doxycycline 40 mg in mild-to-moderate papulopustular rosacea. J Drugs Dermatol 2010, 9(6):607-613.
250. Webster GF An open-label, community-based, 12-week assessment of the effectiveness and safety of monotherapy with doxycycline 40 mg (30-mg immediate-release and 10-mg delayed release beads). Cutis 2010, 86(suppl 5[i]):7-15.
251. Del Rosso JQ Effectiveness and safety of doxycycline 40 mg (30-mg immediate-release and 10-mg delayed release beads) once daily as add-on therapy to existing topical regimens for the treatment of papulopustular rosacea: results from a community-based trial. Cutis 2010, 86(suppl 5[i]):16-25.
252. Del Rosso JQ, Schlessinger J, Werschler P Comparison of anti-inflammatory dose doxycycline versus doxycycline 100 mg in the treatment of rosacea. J Drugs Dermatol 2008, 7(6):573-576.
253. Sanchez J, Somolinos AL, Almodovar PI, et al. A randomized, double-blind, placebo-controlled trial of the combined effect of doxycycline hyclate 20-mg tablets and metronidazole 0.75% topical lotion in the treatment of rosacea. J Am Acad Dermatol 2005, 53:791-797.
254. Berth-Jones J Rosacea. Treatment of Skin Disease: Comprehensive Therapeutic Strategies 2010, 676. Mosby Elsevier, Philadelphia, USA. 3rd ed. M.G. Lebwohl, W.R. Heymann, J. Berth-Jones, I. Coulson (Eds.).
255. Macdonald A, Feiwel M Perioral dermatitis: aetiology and treatment with tetracycline. Br J Dermatol 1972, 87:351-359.
256. Adams SJ, Davison AM, Cunliffe WJ, et al. Perioral dermatitis in renal transplant recipients maintained on corticosteroids and immunosuppressive therapy. Br J Dermatol 1982, 106:589-592.
257. Gupta AK Perioral dermatitis. Evidenced-Based Dermatology 2008, 112-114. Blackwell Publishers, Malden, Massachusetts. 2nd ed. H. Williams, M. Bigby, T. Diepgen, A. Herxheimer, L. Naldi, B. Rzany (Eds.).
258. Bernier C, Dreno B Minocycline. Ann Dermatol Venereol 2001, 128(5):627-637.
259. Berk MA, Lornicz AL The treatment of bullous pemphigoid with tetracycline and nicotinamide: a preliminary report. Arch Dermatol 1986, 122:670-674.
260. Hornschuh B, Hamm H, Wever S, et al. Treatment of 16 patients with bullous pemphigoid with oral tetracycline and nicotinamide and topical clobetasol. J Am Acad Dermatol 1997, 36:101-103.
261. Loo WJ, Kirtschig G, Wojnarowska F Minocycline as a therapeutic option in bullous pemphigoid. Clin Exp Dermatol 2001, 26:376-379.
262. Zemtsov A, Neldner KH Successful treatment of dermatitis herpetiformis with tetracycline and nicotinamide in a patient unable to tolerate dapsone. J Am Acad Dermatol 1993, 28:505-506.
263. Chaffins MI, Collinson D, Fivenson DP Treatment of pemphigus and linear IgA dermatosis with nicotinamide and tetracycline: a review of 13 cases. J Am Acad Dermatol 1993, 28:998-1000.
264. Sperber BR, Martin LK, Murrell D, Werth VP Pemphigus. Evidenced-Based Dermatology 2008, 591. Blackwell Publishers, Malden, Massachusetts. 2nd ed. H. Williams, M. Bigby, T. Diepgen, A. Herxheimer, L. Naldi, B. Rzany (Eds.).
265. Reiche L, Wojnarowska F, Malton E Combination therapy with nicotinamide and tetracyclines for cicatricial pemphigoid: further support for its efficacy. Clin Exp Dermatol 1998, 23(6):254-257.
266. Marshall TG, Marshall FE Sarcoidosis succumbs to antibiotics - implications for autoimmune disease. Autoimmun Rev 2004, 3(4):295-300.
267. Izikson L, English JC Cutaneous sarcoidosis. Evidenced-Based Dermatology 2008, 599. Blackwell Publishers, Malden, Massachusetts. 2nd ed. H. Williams, M. Bigby, T. Diepgen, A. Herxheimer, L. Naldi, B. Rzany (Eds.).
268. Bachelez H, Senet P, Cadranel J, et al. The use of tetracyclines for the treatment of sarcoidosis. Arch Dermatol 2001, 137(1):69-73.
269. Mosam A, Morar N Recalcitrant cutaneous sarcoidosis: an evidence-based sequential approach. J Drugs Dermatolog Treat 2004, 15(6):353-359.
270. Scheinfeld N Confluent and reticulated papillomatosis: a review of the literature. Am J Clin Dermatol 2006, 7(5):305-313.
271. Chang SN, Kim SC, Lee SH, et al. Minocycline treatment for confluent and reticulated papillomatosis. Cutis 1996, 57(6):454-457.
272. Puig L, De Moragas JM Confluent and reticulated papillomatosis of Gougerot and Cateaud: minocycline deserves a trial before etretinate. Arch Dermatol 1995, 131(1):109-110.
273. Gur-Toy G, Gungor E, Artuz F, et al. Prurigo pigmentosa. Int J Dermatol 2002, 41(5):288-291.
274. Cota C, Donati P, Amantea A Prurigo pigmentosa associated with an atopic diathesis in a 13-year old girl. Pediatr Dermatol 2007, 24(3):277-279.
275. Baykal CM, Buyukbalbani N, Akinturk S, et al. Prurigo pigmentosa: not an uncommon disease in the Turkish population. Int J Dermatol 2006, 45(10):1164-1168.
276. Ekmekci TR, Altunay IK, Koslu A Prurigo pigmentosa treated with doxycycline. Dermatol Online 2006, 12(1):9. Jan 27.
277. Sperling LC, Homoky C, Pratt L, et al. Acne keloidalis nuchae is a form of scarring alopecia. Arch Dermatol 2000, 136:479-484.
278. Kohler IK, Lorinez AL Erythema elevatum diutinum treated with niacinamide and tetracycline. Arch Dermatol 1980, 116:693-695.
279. Yotsumoto S, Uchimiya H, Kanzaki T A case of follicular mucinosis treated successfully with minocycline. Br J Dermatol 2000, 142:841-842.
280. Wittenberg GP, Gibson LE, Pittlekow MR, et al. Follicular mucinosis presenting as an acneiform eruption: report of four cases. J Am Acad Dermatol 1988, 38:849-851.
281. Naldi L, Chalmers RJ Psoriasis. Evidenced-Based Dermatology 2008, 185. Blackwell Publishers, Malden, Massachusetts. 2nd ed. H. Williams, M. Bigby, T. Diepgen, A. Herxheimer, L. Naldi, B. Rzany (Eds.).
282. Sturman SW Panniculitis responsive to high dose doxycycline. Arch Dermatol 1975, 111:533-534.
283. Shelley WB, Griffith RF Pityriasis lichenoides et varioliformis acuta. Arch Dermatol 1969, 100:596-597.
284. Piamphongsant T Tetracycline for the treatment of pityriasis lichenoides. Br J Dermatol 1974, 91:319.
285. Graykowski EA, Kingman A Double-blind trial of tetracycline in recurrent aphthous ulceration. J Oral Pathol 1978, 7:376-382.
286. Elston D Methicillin-resistant Staphylococcus aureus (MRSA. Treatment of Skin Disease: Comprehensive Therapeutic Strategies 2010, 449-451. Mosby Elsevier, Philadelphia, USA. 3rd ed. M.G. Lebwohl, W.R. Heymann, J. Berth-Jones, I. Coulson (Eds.).
287. Berbis P Rickettsial infections. Treatment of Skin Disease: Comprehensive Therapeutic Strategies 2006, 580-583. Mosby Elsevier, Philadelphia, USA. 2nd ed. M.G. Lebwohl, W.R. Heymann, J. Berth-Jones, I. Coulson (Eds.).
288. Abramson JS, Givner LB Should tetracycline be contraindicated for therapy of presumed RMSF in children less than 9 years of age?. Pediatrics 1990, 86:123-124.
289. Masters EJ, Olson GS, Weiner SJ, et al. Rocky Mountain spotted fever: a clinician's dilemma. Arch Intern Med 2003, 163:769-774.
290. Rosen T, Vandergriff T, Harting M Antibiotic use in sexually transmitted diseases. Dermatol Clin 2009, 27(1):49-61.
291. High WA Cutaneous infections. General Dermatology (Requisites in Dermatology) 2009, 105-106. Saunders-Elsevier, Philadelphia, USA. K. Schwarzenberger, A.E. Werchniak, C.J. Ko (Eds.).
292. Sanchez M Syphilis. Treatment of Skin Disease: Comprehensive Therapeutic Strategies 2010, 730-733. Mosby Elsevier, Philadelphia, USA. 3rd ed. M.G. Lebwohl, W.R. Heymann, J. Berth-Jones, I. Coulson (Eds.).
293. Steere AC, Hutchinson GJ, Rahn DW, et al. Treatment of the early manifestations of Lyme disease. Ann Intern Med 1983, 99:22-26.
294. Nowakowski J, Nadelman RB, Forseter G, et al. Doxycycline versus tetracycline therapy for Lyme disease associated with erythema migrans. J Am Acad Dermatol 1995, 32(2 Pt 1):223-227.
295. Ogrinc K, Logar M, Lotric-Furian S, et al. Doxycycline versus ceftriaxone for the treatment of patients with chronic Lyme borreliosis. Wien Klin Wochenschr 2006, 118(21-22):696-701.
296. Luger SW, Paparone P, Wormser GP, et al. Comparison of cefuroxime axetil and doxycycline in the treatment of patients with early Lyme disease associated with erythema migrans. Antimicrob Agents Chemother 1995, 39(3):661-667.
297. Patel G, Wallach F Lyme borreliosis. Treatment of Skin Disease: Comprehensive Therapeutic Strategies 2010, 404-406. Mosby Elsevier, Philadelphia, USA. 3rd ed. M.G. Lebwohl, W.R. Heymann, J. Berth-Jones, I. Coulson (Eds.).
298. Sanchez M Pinta and yaws. Treatment of Skin Disease: Comprehensive Therapeutic Strategies 2010, 559-561. Mosby Elsevier, Philadelphia, USA. 3rd ed. M.G. Lebwohl, W.R. Heymann, J. Berth-Jones, I. Coulson (Eds.).
299. Morel P Lymphogranuloma venereum. Treatment of Skin Disease: Comprehensive Therapeutic Strategies 2010, 415-416. Mosby Elsevier, Philadelphia, USA. 3rd ed. M.G. Lebwohl, W.R. Heymann, J. Berth-Jones, I. Coulson (Eds.).
300. Bhambri S, Bhambri A, Del Rosso JQ Atypical mycobacterial cutaneous infections. Dermatol Clin 2009, 27(1):63-73.
301. Majmudar V Mycobacterial (atypical) skin infections. Treatment of Skin Disease: Comprehensive Therapeutic Strategies 2010, 463-467. Mosby Elsevier, Philadelphia, USA. 3rd ed. M.G. Lebwohl, W.R. Heymann, J. Berth-Jones, I. Coulson (Eds.).
302. Wallace RJ, Wiss K Susceptibility of Mycobacterium marinum to tetracyclines and aminoglycosides. Antimicrob Agents Chemother 1981, 20:610-612.
303. Reboli AC, Del Bene VF Oral antibiotics therapy of dermatologic conditions. Dermatol Clin 1988, 6:497-520.
304. Rudikoff D, Gurtman A Bioterrorism. Treatment of Skin Disease: Comprehensive Therapeutic Strategies 2010, 89-95. Mosby Elsevier, Philadelphia, USA. 3rd ed. M.G. Lebwohl, W.R. Heymann, J. Berth-Jones, I. Coulson (Eds.).
305. Elston DM Bites and stings. Treatment of Skin Disease: Comprehensive Therapeutic Strategies 2010, 96-97. Mosby Elsevier, Philadelphia, USA. 3rd ed. M.G. Lebwohl, W.R. Heymann, J. Berth-Jones, I. Coulson (Eds.).
306. Blume JE Actinomycosis. Treatment of Skin Disease: Comprehensive Therapeutic Strategies 2010, 21-23. Mosby Elsevier, Philadelphia, USA. 3rd ed. M.G. Lebwohl, W.R. Heymann, J. Berth-Jones, I. Coulson (Eds.).
307. American Hospital Formulary Service Tetracycline. Drug Information 1995. Am Soc Health Syst Pharm 1995, 95:338-355.
308. Amendda MA, Spera TD Doxycycline induced esophagitis. JAMA 1985, 253:1009-1111.
309. Biller JA, Flores A, Buie T, et al. Tetracycline-induced esophagitis in adolescent patients. J Pediatr 1992, 120:144-145.
310. Akbayir N, Alkim C, Erdem L, et al. A case report of doxycycline induced esophageal and gastric ulcer. Turk J Gastroenterol 2002, 13(4):232-235.
311. Tahan V, Sayrak H, Bayar N, et al. Doxycycline-induced ulceration mimicking esophageal cancer. Cases J 2008, 1(1):144.
312. Gencosmanoglu R, Kurtkaya-Yapicier O, Tiftikci A, et al. Mid-esophageal ulceration and candidiasis-associated distal esophagitis as two distinct clinical patterns of tetracycline and doxycycline-induced esophageal injury. J Clin Gastroenterol 2004, 38:484-489.
313. Alvares JF, Kulkarni SG, Bhatia SJ, et al. Prospective evaluation of medication-induced esophageal injury and its relation to esophageal function. Indian J Gastroenterol 1999, 18(3):115-117.
314. Ovartlarnporn B, Kulwichit W, Hiranniramol S Medication-induced esophageal injury: report of 17 cases with endoscopic documentation. Am J Gastroenterol 1991, 86(6):748-750.
315. Al Mofarreh MA, Al Mofleh IA Doxycycline-induced esophageal ulcerations. Saudi. J Gastroenterol 1998, 4(1):20-24.
316. Barbier P, Dony A, Adler M, et al. Oesophageal ulcerations induced by doxycycline: report of 5 cases. Acta Gastroenterol Belg 1980, 43(5-6):155-166.
317. Delpre G, Kadish U, Stahl B Induction of esophageal injuries by doxycycline and other pills: a frequent but preventable occurrence. Dig Dis Sci 1989, 3(4):797-800.
318. Shils ME, Ren Akbayir N, Alkim C, Erdem L, et al. A case report of doxycycline induced esophageal and gastric ulcer. Turk J Gastroenterol 2002, 13(4):232-235.
319. Elmore MF, Rogge JD Tetracycline induced pancreatitis. Gastroenterology 1981, 81:1134-1136.
320. Minocin(r) (minocycline HCl). Full Prescribing Information, Triax Pharmaceuticals, Cranford, NJ, 2010.
321. Adoxa(r) (doxycycline capsules,USP). Full Prescribing Information, Pharmaderm (division of Nycomed), Melville, NY, 2008.
322. Monodox(r) (doxycycline monohydrate capsules). Full Prescribing Information, Aqua Pharmaceuticals, Malvern, PA, 2006.
323. Doryx(r) (doxycycline hyclate enteric-coated tablets), Full Prescribing Information, Warner Chilcott, Rockaway, NJ, 2008.
324. Shapiro LE, Knowles SR, Shear NH Comparative safety of tetracycline, minocycline, and doxycycline. Arch Dermatol 1997, 133(10):1224-1230.
325. Del Rosso JQ Systemic therapy for rosacea: focus on oral antibiotic therapy and safety. Cutis 2000, 66(4 Suppl):7-13.
326. Goulden V, Glass D, Cunliffe WJ Safety of long-term high-dose minocycline in the treatment of acne. Br J Dermatol 1996, 134(4):693-695.
327. Friedman DI Medication-induced intracranial hypertension in dermatology. Am J Clin Dermatol 2005, 6(1):29-37.
328. Yong CK, Prendiville J, Peacock DL, et al. An unusual presentation of doxycycline-induced photosensitivity. Pediatrics 2000, 106(1):E13.
329. Tanaka N, Kawada A, Ohnishi Y, et al. Photosensitivity due to doxycycline hydrochloride with an unusal flare. Contact Dermatitis 1997, 37(2):93-94.
330. Zuehlke RL Papular doxycycline photosensitivity. Arch Dermatol 1973, 108(6):837-838.
331. Bjellerup M Medium-wave ultraviolet radiation (UVB) is important in doxycycline photoxicity. Acta Derm Venereol 1986, 66(6):510-514.
332. Lasarow RM, Isseroff RR, Gomez EC Quantitative in vitro assessment of phototoxicity by a fibroblast-neutral red assay. J Invest Dermatol 1992, 98(5):725-729.
333. Glette J, Sandberg S Phototoxicity of tetracyclines as related to singlet oxygen production and uptake by polymorphonuclear leukocytes. Biochem Pharmacol 1986, 35(17):2883-2885.
334. Passier A, Smits-Herwaarden A, van Puijenbroek E Photo-onycholysis associated with the use of doxycycline. BMJ 2004, 329(7460):265.
335. Carroll LA, Laumann AE Doxycycline-induced photo-onycholysis. J Drugs Dermatol 2003, 2(6):662-663.
336. Baran R, Juhlin L Drug-induced photo-onycholysis: three subtypes identified in a study of 15 cases. J Am Acad Dermatol 1987, 17(6):1012-1016.
337. Ochsendorf F Minocycline in acne vulgaris: benefits and risks. Am J Clin Dermatol 2010, 11(5):327-341.
338. Fenske NA, Millns JL, Greer KE Minocycline induced pigmentation at sites of cutaneous inflammation. JAMA 1980, 244(10):1103-1106.
339. Ridgway HA, Sonnex TS, Kennedy CT, et al. Hyperpigmentation associated with oral minocycline. Br J Dermatol 1982, 107:95-102.
340. Wolfe ID, Reichmister J Minocycline hyperpigmentation: skin, tooth, nail, and bone involvement. Cutis 1984, 33(5):457-478.
341. Wienrich BG, Bertsch HP, Schon MP, et al. Dark grey hyperpigmentation on the face and neck: minocycline-induced hyperpigmentation type III. J Dtsch Dermatol 2010, 8(7):544-546.
342. Karrer S, Szeimies RM, Pfau A, et al. Minocycline-induced hyperpigmentation. Hautarzt 1998, 49(3):219-223.
343. Treister NS, Magalnick D, Woo SB Oral mucosal pigmentation secondary to minocycline therapy: report of two cases and review of the literature. Oral Surg Oral Med. Pathol Oral Radiol Endod 2004, 97(6):718-725.
344. Patterson W, Wilson B, Wick MR, et al. Hyperpigmented scar due to minocycline therapy. Cutis 2004, 74(5):293-298.
345. Meyer AJ, Nahass GT Hyperpigmented patches on the dorsa of the feet: minocycline hyperpigmentation. Arch Dermatol 1995, 131(12):1447. 1450.
346. Hung PH, Caldwell JB, James WD Minocycline-induced hyperpigmentation. J Fam Pract 1995, 41(2):183-185.
347. Prigent F, Cavelier-Balloy B, Tollenaere C, et al. Cutaneous pigmentation induced by minocycline: 2 cases. Ann Dermatol Venereol 1986, 113(3):227-233.
348. Leffell CJ Minocycline hydrochloride hyperpigmentation complicating treatment of venous ectasia of the extremities. J Am Acad Dermatol 1991, 24(3):501-502.
349. Altman DA, Fivenson DP, Lee MW Minocycline hyperpigmentation: model for in situ phagocytic activity of factor XIIIa positive dermal dendrocytes. J Cutan Pathol 1992, 19(4):340-345.
350. Roberts G, Capell HA The frequency of minocycline hyperpigmentation in a rheumatoid arthritis population. J Rheumatol 2006, 33:1254-1257.
351. Chatterjee S Hyperpigmentation associated with minocycline therapy. CMAJ 2007, 176(3):321-322.
352. Simons JJ, Morales A Minocycline and generalized cutaneous pigmentation. J Am Acad Dermatol 1980, 3(3):244-247.
353. Eedy DJ, Burrows D Minocycline-induced facial pigmentation occurring in two sisters. Clin Exp Dermatol 1991, 16(1):56-57.
354. Mooney E, Bennett RG Periungual hyperpigmentation mimicking Hutchinson's sign associated with minocycline administration. J Dermatol Surg Oncol 1988, 14(9):1011-1013.
355. Sanchez JJ, Rogers RS, Sheridan PJ Tetracycline and other tetracycline-derivative staining of the teeth and oral cavity. Int J Dermatol 2004, 43(10):709-715.
356. Geria AN, Tajirian AL, Kihiczak G, et al. Minocycline-induced hyperpigmentation: an update. Acta Dermatovenerol Croat 2009, 17(2):123-126.
357. Mouton RW, Jordaan HF, Schneider JW A new type of minocycline-induced cutaneous hyperpigmentation. Clin Exp Dermatol 2004, 29(1):8-14.
358. Gordon G, Sparano BM, Iatropoulos MJ Hyperpigmentation of the skin associated with minocycline therapy. Arch Dermatol 1985, 121(5):618-623.
359. Argenyi ZB, Finelli L, Bergfeld WF, et al. Minocycline-related cutaneous hyperpigmentation as demonstrated by light microscopy, electron microscopy, and x-ray energy spectroscopy.
360. Sato S, Murphy GS, Bernhard JD, et al. Ultrastructural and x-ray microanalytical observations of minocycline-related hyperpigmentation of the skin. J Invest Dermatol 1981, 77(3):264-271.
361. Bowen AR, McCalmont TH The histopathology of subcutaneous minocycline pigmentation. J Am Acad Dermatol 2007, 57(5):836-839.
362. Dodiul RP, de Morentin HM, Schafer J, et al. Minocycline-induced cutaneous hyperpigmentation: confocal laser scanning microscope analysis. J. Europ Acad Dermatol Venereol 2006, 20(4):435-439.
363. Knoell KA, Milgraum SS, Kutenplon M Q-switched ruby laser treatment of minocycline-induced cutaneous hyperpigmentation. Arch Dermatol 1996, 132(10):1251-1253.
364. Tsao H, Busam K, Barnhill R, et al. Treatment of minocycline-induced hyperpigmentation with the Q-switched ruby laser. Arch Dermatol 1996, 132(10):1250-1251.
365. Friedman IS, Shelton RM, Phelps RG Minocycline-induced hyperpigmentation of the tongue: successful treatment with the Q-switched ruby laser. Dermatol Surg 2002, 28(3):205-209.
366. Alster TS, Gupta SN Minocycline-induced hyperpigmentation treated with a 755-nm Q-switched alexandrite laser. Dermatol Surg 2004, 30(9):1201-1204.
367. Izikson L, Anderson RR Resolution of blue minocycline pigmentation of the face after fractional photothermolysis. Lasers Surg Med 2008, 40(6):399-401.
368. Soung J, Cohen J, Phelps R, et al. Case reports: minocycline-induced hyperpigmentation resolves during oral isotretinoin therapy. J Drugs Dermatol 2007, 6(12):1232-1236.
369. Akcam M, Artan R, Akcam FZ, et al. Nail discoloration induced by doxycycline. Pediatr Infect Dis 2005, 24(9):845-846.
370. Bohm M, Schmidt PF, Lodding B, et al. Cutaneous hyperpigmentation induced by doxycycline: histochemical and ultrastructural examination, laser microprobe mass analysis, and cathodoluminescence. Am J Dermatopath 2002, 24(4):345-350.
371. Del Rosso JQ. Acne therapy update. Presented at Fall Clinical Dermatology, Las Vegas, Nevada, October 2008.
372. IMS NPA Database, IMS Health and Informatics, San Antonio, Texas, accessed 12/27/10.
373. Bjornberg A, Roupe G Susceptibility to infections during long term treatment with tetracyclines in acne vulgaris. Dermatologica 1972, 14:334-337.
374. Blankenship ML Gram-negative folliculitis. Arch Dermatol 1984, 120:1301-1303.
375. Leyden JJ, Marples RR, Mills OH, et al. Gram-negative folliculitis: a complication of antibiotic therapy in acne vulgaris. Br J Dermatol 1973, 88:533-538.
376. Gendernalik SB, Galeckas KJ Fixed drug eruptions: a case report and review of the literature. Cutis 2009, 84(4):215-219.
377. Cohen PR, Kurzrock R Sweet's syndrome revisited: a review of disease concepts. Int J Dermatol 2003, 42:761-778.
378. Khan Durani B, Jappe U Drug-induced Sweet's syndrome in acne caused by different tetracyclines: case report and review of the literature. Br J Dermatol 2002, 147(3):558-562.
379. Lefebvre N, Forestier E, Farhi D, et al. Minocycline-induced hypersensitivity syndrome presenting with meningitis and brain edema: a case report. J Med Case Reports 2007, 1:22.
380. Tsuruta D, Someda Y, Sowa J, et al. Drug hypersensitivity syndrome caused by minocycline. J Cutan Med Surg 2006, 10(3):131-135.
381. Piette AM, Ramanoelina J, Gepner P, et al. Systemic reaction induced by minocycline treatment: a report of four patients and a review of the literature. Rev Med Interne 1999, 20(10):869-874.
382. Roujeau JC, Stern RS Severe adverse cutaneous reactions to drugs. N Engl J Med 1994, 331:1272-1285.
383. Shaughnessy KK, Bouchard SM, Mohr MR, et al. Minocycline-induced drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome with persistent myocarditis. J Am Acad Dermatol 2010, 62(2):315-318.
384. Brown RJ, Rother KI, Artman H, et al. Minocycline-induced drug hypersensitivity syndrome followed by multiple autoimmune sequelae. Arch Dermatol 2009, 145(1):63-66.
385. Oddo M, Liaudet L, Lepori M, et al. Relapsing acute respiratory failure induced by minocycline. Chest 2003, 123(6):2146-2148.
386. Eikayam O, Yaron M, Caspi D Minocycline-induced autoimmune syndrome: an overview. Semin Arthritis Rheum 1999, 28(6):392-397.
387. Robles DT, Leonard JL, Compton N, et al. Severe drug hypersensitivity in a young woman treated with doxycycline. Dermatology 2008, 217(1):23-26.
388. Maihol C, Tremeau-Martinage C, Paul C, et al. Severe drug hypersensitivity reaction (DRESS) syndrome to doxycycline. Ann Dermatol Venereol 2010, 137(1):40-43.
389. Yoon J, Lee SH, Kim TH, et al. Concurrence of Stevens-Johnson syndrome and bilateral parotitis after minocycline therapy. Case Rep Dermatol 2010, 2(2):88-94.
390. Cac NN, Messingham MJ, Sniezek PJ, et al. Stevens-Johnson syndrome induced by doxycycline. Cutis 2007, 79(2):119-122.
391. Lau B, Mutyala D, Dhaliwal D A case report of doxycycline-induced Stevens-Johnson syndrome. Cornea Nov 2010, (Epub).
392. Margolis DJ, Hoffstad O, Bilker W Association or lack of association between tetracycline class antibiotics for acne vulgaris and lupus erythematosus. Br J Dermatol 2007, 157(3):540-546.
393. Mongey AB, Hess AV Drug insight: autoimmune effects of medications - what's new?. Natl Clin Pract Rheumatol 2008, 4(3):136-144.
394. Marzo-Ortega H, Baxter K, Czirjak L, et al. Is minocycline therapy in acne associated with antineutrophil cytoplasmic antibody positivity? A cross-sectional study. Br J Dermatol 2007, 156(5):1005-1009.
395. Dunphy J, Oliver M, Rands AL Antineutrophilic cytoplasmic antibodies and HLA class II alleles in minocycline-induced lupus-like syndrome. Br J Dermatol 2000, 142(3):461-467.
396. Schlienger RG, Bircher AJ, Meier CR Minocycline-induced lupus: a systematic review. Dermatology 2000, 200(3):223-231.
397. Eichenfield AH Minocycline and autoimmunity. Curr Opin Pediatr 1999, 11(5):447-456.
398. Knights SE, Leandro MJ, Khamashta MA, et al. Minocycline-induced arthritis. Clin Exp Rheumatol 1998, 16(5):587-590.
399. Mannargudi B, McNally D, Reynolds W, et al. Bioactivation of minocycline to reactive metabolites by myeloperoxidases, horseradish peroxidase, and hepatic microsomes. Drug Metab Dispos 2009, 37(9):1806-1818.
400. Sturkenboom MC, Meier CR, Jick H, et al. Minocycline and lupuslike syndrome in acne patients. Arch Intern Med 1999, 159(5):493-497.
401. Benjamin RW, Calikoglu AS Hyperthyroidism and lupus-like syndrome in an adolescent treated with minocycline for acne. Pediatr Dermatol 2007, 24(3):246-249.
402. Porter D, Harrison A Minocycline-induced lupus: a case series. NZ Med J 2003, 116(1171):U384.
403. Christodoulou CS, Emmanuel P, Ray RA, et al. Respiratory distress due to minocycline-induced pulmonary lupus. Chest 1999, 115(5):1471-1473.
404. Ahmed F, Kelsey PR, Shariff N Lupus syndrome with neutropenia following minocycline therapy - a case report. Int J Lab Hematol 2008, 30(6):543-545.
405. D'Addano SF, Bryan ME, Stinger WA, et al. Minocycline-induced immune thrombocytopenia presenting as Schamberg's disease. J Drugs Dermatol 2003, 2(3):320-323.
406. Egger SS, Studer IG, Ratz Bravo AE, et al. Minocycline-induced lupus erythematodes. Praxis (Bern) 2006, 95(35):1297-1303.
407. Lawson TM, Amos N, Bulgen D, et al. Minocycline-induced lupus: clinical features and response to rechallenge. Rheumatology 2001, 40(3):329-335.
408. Angulo JM, Sigal LH, Espinoza LR Coexistent minocycline-induced systemic lupus erythematosus and autoimmune hepatitis. Semin Arthritis Rheum 1998, 28(3):187-192.
409. Marzano AV, Vezzoli P, Crosti C Drug-induced lupus: an update on dermatologic aspects. Lupus 2009, 18(11):935-940.
410. Marai I, Shoenfeld Y Lupus-like disease due to minocycline. Harefuah 2002, 141(2):151-152.
411. Chang C, Gershwin ME Drugs and autoimmunity-a contemporary review and mechanistic approach. J Autoimmun 2010, 34(3):J266-J275.
412. Tehrani R, Nash-Goelitz A, Adams E, et al. Minocycline-induced cutaneous polyarteritis nodosa. J Clin Rheumatol 2007, 13(3):146-149.
413. Sakai H, Komatsu S, Matsuo S, et al. Two cases of minocycline-induced vasculitis. Arerugi 2002, 51(12):1153-1158.
414. Schaffer JV, Davidson DM, McNiff JM, et al. Perinuclear antineutrophilic cytoplasmic antibody-positive cutaneous polyarteritis nodosa associated with minocycline therapy for acne vulgaris. J Am Acad Dermatol 2001, 44(2):198-206.
415. Lawrenson RA, Seaman HE, Sundstrom A, et al. Liver damage associated with minocycline use in acne: a systematic review of the published literature and pharmacovigilance data. Drug Saf 2000, 23(4):333-349.
416. Herzog D, Hajoui O, Russo P, et al. Study of immune reactivity of minocycline-induced chronic active hepatitis. Dig Dis Sci 1997, 42(5):1100-1103.
417. Chamberlain MC, Schwarzenberg SJ, Akin AU, et al. Minocycline-induced autoimmune hepatitis with subsequent cirrhosis. J Pediatr Gastroenterol 2006, 42(2):232-235.
418. Briggs GG, Freeman RK, Yaffe SJ Tetracycline. Drugs in Pregnancy and Lactation 2005, 1549-1553. Lippincott Williams & Wilkins, Philadelphia. 7th ed. G.G. Briggs, R.K. Freeman, S.J. Yaffe (Eds.).
419. Shils ME Renal disease and the metabolic effects of tetracycline. Ann Intern Med 1963, 58:389-408.
420. Hunt MJ, Salisbury ELC, Grace J, et al. Black breast milk due to minocycline therapy. Br J Dermatol 1996, 134:943-944.
421. Committee on Drugs American Academy of Pediatrics. The transfer of drugs and other chemicals into human milk. Pediatrics 2001, 108:776-789.
422. Tatro DS Drug Interactions Facts 2006, Wolters Kluwer Health, St. Louis, pp. 155, 567, 805, 883, 966, 1434.
423. Archer JS, Archer DF Oral contraceptive efficacy and antibiotic interaction: a myth debunked. J Am Acad Dermatol 2002, 46(6):917-923.
424. Dickinson BD, Altman RD, Nielsen NH, et al. Drug interactions between oral contraceptives and antibiotics. Obstet Gynecol 2001, 98(5 Pt 1):853-860.
425. Miller DM, Helms SE, Brodell RT A practical approach to antibiotic treatment in women taking oral contraceptives. J Am Acad Dermatol 1994, 30(6):1008-1011.
426. Helms SE, Bredle DL, Zajic J, et al. Oral contraceptive failure rates and oral antibiotics. J Am Acad Dermatol 1997, 36(5 Pt 1):705-710.
427. Tatro DS Drug Interactions Facts 2006, Wolters Kluwer Health, St. Louis.
428. Accutane(r) (isotretinoin). Full Prescribing Information, Roche Pharmaceuticals, Nutley, NJ, 2001.
429. Rifadin(r) (rifampin oral capsules and for injection) Full Prescribing Information 2007, Sanofi-Aventis, Bridgewater, NJ.
430. Katzung, Bertram G Basic and Clinical Pharmacology 2009, Lange Medical Books/McGraw-Hill, New York, pp. 823-34. 11th ed.
431. Thornsberry C, Hill BC, Swenson JM, et al. Rifampin: spectrum of antibacterial activity. Rev Infect Dis 1983, 5(suppl 3):412-417.
432. Perlroth J, Kuo M, Tan J, et al. Adjunctive use of rifampin for the treatment of Staphylococcus aureus infections: a systematic review of the literature. Arch Intern Med 2008, 168(8):805-819.
433. Cohen PR Community-acquired methicillin-resistant Staphylococcus aureus skin infection presenting as an axillary abscess with cellulitis in a college student. SkinMed: Dermatology for the Clinician 2005, 4:115-118. ID: 3866. http://http://www.lejacq.com.
434. Prescott JF Rhodococcus equi: an animal and human pathogen. Clin Microbiol Rev 1991, 4:20-34.
435. O'Brien RJ, Lyle MA, Snider DE Rifabutin (Ansamycin LM427): a new rifamycin-S derivative for the treatment of mycobacterial diseases. Rev Infect Dis 1987, 9:519-530.
436. Brogden RN, Fitton A Rifabutin. A review of its anti-microbial activity, pharmacokinetic properties and therapeutic efficacy. Drugs 1994, 47:983-1009.
437. Steffen R, Sack DA, Riopel L, et al. Therapy of traveler's diarrhea with rifaximin on various continents. Am J Gastroenterol 2003, 98:1073-1078.
438. Purohit SD, Supta ML, Gupia PR Dietary constituents and rifampicin absorption. Tuberculosis 1987, 68:151.
439. Tsankov N, Angelova I Rifampin in dermatology. Clin Dermatol 2003, 21(1):50-55.
440. Briggs GG, Freeman RK, Yaffe SJ Rifabutin, Rifampin, Rifapentine. Drugs in Pregnancy and Lactation 2005, 1412-1416. Lippincott Williams & Wilkins, Philadelphia. 7th ed. G.G. Briggs, R.K. Freeman, S.J. Yaffe (Eds.).
441. Eggermont E, Logghe N, Van De Casseye ••, et al. Hemorrhagic disease of the newborn in the offspring of rifampicin and isoniazid treated mothers. Acta Paediatr Belg 1976, 29:87-90.
442. Baciewicz AM, Chrisman CR, Finch CK, et al. Update on rifampin and rifabutin drug interactions. Am J Med Sci 2008, 335(2):126-136.
443. Xifaxan(r) (rifaximin tablets), Full Prescribing Information 2004, Salix Pharmaceuticals, Raleigh, NC.
444. Steffen R Rifaximin: a nonabsorbed antimicrobial as a new tool for treatment of travelers' diarrhea. J Travel Med 2001, 8:34-39.
445. Ramesh V, Misra RS, Saxena V, et al. A comparative of efficacy of drug regimens in skin tuberculosis. Clin Exp Dermatol 1991, 16:106-109.
446. Griffith DE, Aksamit T, Brown-Elliot BA, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial disease. Am J Respir Crit Care Med 2007, 175:367-416.
447. Ladhani S, Zhang W Leprosy. Evidenced-Based Dermatology 2008, 443-446. Blackwell Publishers, Malden, Massachusetts. 2nd ed. H. Williams, M. Bigby, T. Diepgen, A. Herxheimer, L. Naldi, B. Rzany (Eds.).
448. Rallis EE, Koumantaki-Mathioudaki E Treatment of Mycobacterium marinum cutaneous infections. Exp Opin Pharmocother 2007, 8:2965-2978.
449. Lewis FM, Marsh BJ, von Reyn CF Fish tank exposure and cutaneous infections due to Mycobacterium marinum: tuberculin skin testing, treatment and prevention. Clin Infect Dis 2003, 37:390-397.
450. Anon. Updated guidelines for the use of rifabutin or rifampin for the treatment and prevention of tuberculosis among HIV-infected patients taking protease inhibitors or nonnucleoside reverse transcriptase inhibitors. MMWR Morb Mortal Wkly Rep 2000, 49:185-189.
451. Conrad DA Treatment of car-scratch disease. Curr Opin Pediatr 2001, 13:56-59.
452. Cunningham ET, Koehler JE Ocular bartonellosis. Am J Ophthalmol 2000, 130:340-349.
453. Smith DL Cat-scratch disease and related clinical syndromes. Am Fam Physician 1997, 55:1783-1789.
454. Cohen PR Cutaneous community-acquired methicillin-resistant Staphylococcus aureus infection in participants of athletic activities. South Med J 2005, 98:596-602.
455. Hoss DM, Feder HM Addition of rifampicin to conventional therapy for recurrent furunculosis. Arch Dermatol 1995, 131:647-648.
456. Rasmussen JE Treatment of nasal carriage of Staphylococcus aureus. Cutaneous Infection and Therapy 1997, 25-28. Marcel Dekker, New York. R. Aly, K.R. Beutner, H. Maibach (Eds.).
457. Gamea AM, El-Tatawi FA The effect of rifampicin on rhinoscleroma: an electron microscopic study. J Laryngol Otol 1990, 104:772-777.
458. Tsankov N, Krasteva M Rifampin therapy in severe forms of psoriasis. J Dermatol Treat 1992, 3:69-71.
459. Green MS, Prystowsky JH, Cohen SR, et al. Infectious complications of erythrodermic psoriasis. J Am Acad Dermatol 1996, 34:911-914.
460. Leung DYM, Travers JB, Giorno R, et al. Evidence for streptococcal superantigen driven process in acute guttate psoriasis. J Clin Invest 1995, 96:2006-2012.
461. Vincent F, Ross JB, Dalton M, et al. A therapeutic trial of the use of penicillin V or erythromycin with or without rifampin in treatment of psoriasis. J Am Acad Dermatol 1992, 26:458-461.
462. Bachs L, Pares A, Elena M, et al. Effects of long-term rifampin administration on primary biliary cirrhosis. Gastroenterology 1992, 102:2007-2080.
463. Borcherding SM, Baciewicz AM, Self TH Update on rifampin drug interactions. Arch Intern Med 1992, 152:711-716.
464. Grosset J, Leventis S Adverse effects of rifampin. Rev Infect Dis 1983, 5(Suppl 3):S440-S446.
465. Martinez E, Collazos J, Mayo J Hypersensitivity reactions to rifampin: Pathogenetic mechanisms, clinical manifestations, management strategies, and review of the anaphylactic-like reactions. Medicine 1999, 78(6):361-369.
466. Priftin(r) (rifapentine), Full Prescribing Information, Sanofi-Aventis. Bridgewater, NJ, 2006.
467. Centers for Disease Control and Prevention Treatment of tuberculosis, American Thoracic Society, CDC and Infectious Diseases Society of America. MMWR Recomm Rep 2003, 52(RR-11):1-77.
468. Snider DE, Powell KE Should women taking antituberculous drugs breast-feed?. Arch Intern Med 1984, 144:589-590.
469. Drayton J, Dickinson G, Rinaldi MG Coadministration of rifampin and itraconazole leads to undetectable levels of serum itraconazole. Clin Infect Dis 1994, 18:266.
470. Krajewski KC Inability to achieve a therapeutic INR while on concurrent warfarin and rifampin. J Clin Pharmacol 2010, 50(6):710-713.
471. Hansten PD, Horn JR Managing Clinically Important Drug Interactions 2004, Wolters Kluwer Health, St. Louis, pp. 230, 256-57, 294, 313, 320, 379, 394, 418, 468, 477, 487, 514, 535, 541, 558, 589, 602, 615, 624-629, 630.
472. Hansten PD, Horn JR Managing Clinically Important Drug Interactions 2004, Wolters Kluwer Health, St. Louis, pp. 230, 256-57, 294, 313, 320, 379, 394, 418, 468, 477, 487, 514, 535, 541, 558, 589, 602, 615, 624-629, 630.
473. Hansten PD, Horn JR Managing Clinically Important Drug Interactions 2004, Wolters Kluwer Health, St. Louis, pp. 230, 256-57, 294, 313, 320, 379, 394, 418, 468, 477, 487, 514, 535, 541, 558, 589, 602, 615, 624-629, 630.
474. Bactrim(r) (trimethoprim and sulfamethoxazole), Full Prescribing Information 1998, Roche Pharmaceuticals, Nutley, NJ.
475. Fuchs SM, Elsner P Sulfonamides in dermatology. Clin Dermatol 2003, 21(1):7-11.
476. Cockerill FR, Edson RS Trimethoprim-sulfamethoxazole. Mayo Clin Proc 1991, 66:1260-1269.
477. Smego RA, Moeller MB, Gallis HA Trimethoprim-sulfamethoxazole therapy for Nocardia infections. Arch Intern Med 1983, 143:711-718.
478. Spitzer PG, Hammer SM, Karchmer AW Treatment of Listeria monocytogenes infection with trimethoprim-sulfamethoxazole: case report and review of the literature. Rev Infect Dis 1986, 8:427-430.
479. AHFS Drug Information 2004. Co-trimoxazole 2004, 420-428. American Society of Health System Pharmacists. G.K. McEvoy (Ed.).
480. Briggs GG, Freeman RK, Yaffe SJ Sulfonamides, Trimethoprim. Drugs in Pregnancy and Lactation 2005, 1508-1511. Lippincott Williams & Wilkins, Philadelphia, 1632-1635. 7th ed. G.G. Briggs, R.K. Freeman, S.J. Yaffe (Eds.).
481. Bhambri S, Del Rosso J, Desai A Oral Trimethoprim/Sulfamethoxazole in the treatment of acne vulgaris. Cutis 2007, 79:430-434.
482. Epstein ME, Amodio-Groton MA, Sadick NA Antimicrobial agents for the dermatologist. II. Macrolides, fluoroquinolones, rifamycins, tetracyclines, trimethoprim-sulfamethoxazole and clindamycin. J Am Acad Dermatol 1997, 37:365-381.
483. Momin SB, Richardson BS, Bryan MG, et al. Mycetoma clinically masquerading as squamous cell carcinoma: case report and literature review. J Clin Aesthetic Dermatol 2009, 2(2):26-31.
484. Magana M, Magana-Garcia M Mycetoma. Dermatol Clin 1989, 7:203-217.
485. Margileth AM Antibiotic therapy for cat-scratch disease: clinical study of the therapeutic outcome in 268 patients and a review of the literature. Pediatr Infect Dis J 1992, 11:477-478.
486. Gold WI, Salit IE Aeromonas hydrophilia infections of skin and soft tissue: report of 11 cases and review. Clin Infect Dis 1993, 16:69-74.
487. Sookprance M, Boonma P, Susaengrat W, et al. Multicenter positive randomized trial comparing ceftazidime plus cotrimoxazole with chloramphenicol plus doxycycline and cotrimoxazole for treatment of severe melioidosis. Antimicrob Agents Chemother 1992, 36:158-162.
488. Tran D Cutaneous melioidosis. Clin Exp Dermatol 2002, 27:280.
489. Pereira RM, Bucaretchi F, Barison EM, et al. Paracoccidioidomycosis in children: clinical presentation, follow-up, and outcome. Rev Inst Med Trop Sao Paolo 2004, 46:127-131.
490. Peterson JD, Chan LS Linear IgA bullous dermatosis responsive to trimethoprim-sulfamethoxazole. Clin Exp Dermatol 2007, 32:756-758.
491. Tzortzatou-Stathopoulou F, Xaidara A, Mikraki V, et al. Effect of trimethoprim-sulfamethoxazole in Langerhans' cell histiocytosis: preliminary observations. Med Pediatr Oncol 1995, 25:74-78.
492. Hipolito RB, Mallorca FG, Zuniga-Macaraiq ZO, et al. Head lice infestation: single drug versus combination therapy with one percent permethrin and trimethoprim-sulfamethoxazole. Am J Trop Med Hyg 1995, 53:652-653.
493. Shashindran CH, Gandhi IS, Nrishnasamy S, et al. Oral therapy of pediculosis capitis with cotrimoxazole. Br J Dermatol 1978, 98:699-700.
494. Shashindran CH, Ghandi IS, Lal S Br J Dermatol 1979, 100:483.
495. Gordin F, Gilbert C, Schmidt ME Clostridium difficile colitis associated with trimethoprim- sulfamethoxazole given as prophylaxis for Pneumocystis carinii pneumonia. Am J Med 1994, 96:94-95.
496. Scott SA Trimethoprim/sulfamethoxazole-associated pseudomembranous colitis. Drug Intell Clin Pharm 1982, 16:244-247.
497. Schopf E Skin reactions to co-trimoxazole. Infection 1987, 15(suppl 5):S254-S258.
498. Gimnig J, MacArthur J, M'bang'ombe M, et al. Severe cutaneous reactions to sulfadoxine-pyramethamine and trimethoprim-sulfamethoxazole in Blantyre District, Malawi. Am J Trop Med Hyg 2006, 74:738-743.
499. Remlinger KA Hematologic toxicity of drug therapy. Comprehensive Dermatologic Drug Therapy 2007, 893-909. WB Saunders, Philadelphia, PA. 2nd ed. S.E. Wolverton (Ed.).
500. Knowles SR, Shear NH Drug hypersensitivity syndromes. Comprehensive Dermatologic Drug Therapy 2001, 872-884. WB Saunders, Philadelphia, PA. 1st ed. S.E. Wolverton (Ed.).
501. Bissonnette R, Tousignant J, Allaire G Drug induced toxic pustuloderma. Int J Dermatol 1992, 31:172-174.
502. Walker DC, Cohen PR Trimethoprim-sulfamethoxazole associated acute febrile neutrophilic dermatosis. Case report and review of drug induced Sweet's syndrome. J Am Acad Dermatol 1996, 34:918-923.
503. Munoz SJ, Martinez-Hernandez A, Maddrey WC Intrahepatic cholestasis and phospholipidosis associated with the use of trimethoprim-sulfamethoxazole. Hepatology 1990, 12:342-347.
504. Bergus G Urinary tract infections in pregnancy. Drug Therapy in Pregnancy 2001, 68-69. Lippincott Williams & Wilkins, Philadelphia, PA. 3rd ed. J. Yankowitz, J.R. Niebyl (Eds.).
505. Hansten PD, Horn JR Managing Clinically Important Drug Interactions 2004, Wolters Kluwer Health, St. Louis, pp. 266, 334, 523, 594, 661.
506. Tatro DS Drug Interactions Facts 2006, Wolters Kluwer Health, St. Louis, p. 489.
507. Antoniou T, Gomes T, Juurlink DN, et al. Trimethoprim-sulfamethoxazole-induced hyperkalemia in patients receiving inhibitors of the renin-angiotensin system. Arch Intern Med 2010, 170(12):1045-1049.
508. McGehee RF, Smith CB, Wilcox C, et al. Comparative studies of antibacterial activity in vitro and absorption and excretion of lincomycin and clindamycin. Am J Med Sci 1968, 256:279-292.
509. Cleocin(r) (clindamycin capsules), Full Prescribing Information, Upjohn Pharmaceuticals 1991, Kalamazoo, MI.
510. Sutter VL In vitro susceptibility of anaerobes: comparison of clindamycin and other antimicrobial agents. J Infect Dis 1977, 135:7-12.
511. Dhawan VK, Thadepalli H Clindamycin: a review of fifteen years of experience. Rev Infect Dis 1982, 4:1133-1153.
512. Klempner MS, Styrt B Prevention of recurrent staphylococcal skin infections with low dose oral clindamycin therapy. JAMA 1988, 260:2682.
513. Falagas ME, Gorbach SL Clindamycin and metronidazole. Med Clin North Am 1995, 79:845-867.
514. Anonymous.Clindamycin American Hospital Formulary Service. Drug Information 1995. Am Soc Health Syst Pharm 1995, 357-361.
515. Bartlett JG Antimicrobial agents implicated in Clostridium difficile toxin associated diarrhea or colitis. Johns Hopkins Med J 1981, 149:6-9.
516. Briggs GG, Freeman RK, Yaffe SJ Clindamycin. Drugs in Pregnancy and Lactation 2005, 343-344. Lippincott Williams & Wilkins, Philadelphia. 7th ed. G.G. Briggs, R.K. Freeman, S.J. Yaffe (Eds.).
517. Meagher AK, Ambrose PG, Grasela TH, et al. The pharmacokinetic and pharmacodynamic profile of Tigecycline. Clin Infect Dis 2005, 41:S333-S340.
518. Zhanel GG, Homenuik K, Nichol K, et al. The glycylcyclines: a comparative review with the tetracyclines. Drugs 2004, 64(1):63-88.
519. Meagher AK, Ambrose PG, Grasela TH, et al. Pharmacokinetic/pharmacodynamic profile for tigecycline-a new glycylcycline antimicrobial agent. Diagn Microbiol Infect Dis 2005, 52(3):165-171.
520. Kasbekar N Tigecycline: A new glycylcycline antimicrobial agent. Am J Health Syst Pharm 2006, 63:1235-1243.
521. Fritsche TR, Sader HS, Stilwell MG, et al. Antimicrobial activity of tigecycline tests against organisms causing community-acquired respiratory tract infection and nosocomial pneumonia. Diagn Microbiol Infect Dis 2005, 52:187-193.
522. Ellis-Grosse EJ, Babinchak T, Dartois N, et al. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam. Clin Infect Dis 2005, 41(Suppl 5):S341-S353.
523. Tygacil (r) (tigecycline for injection), Full Prescribing Information 2005, Wyeth Pharmaceuticals Inc, Philadelphia, PA.
524. Hung WY, Kogelman L, Volpe G, et al. Tigecycline-induced acute pancreatitis: case report and literature review. In J Antimicrob Agents 2009, 34(5):486-489.
525. Lundstrom TS, Sobel JD Antibiotics for Gram-positive bacterial infections: vancomycin, quinupristin-dalfopristin, linezolid, and daptomycin. Infect Dis Clin N Amer 2004, 18(3):651-658.
526. Wesson KM, Lerner DS, Silverberg NB, Weinberg JM Linezolid, quinupristin/dalfopristin, and daptomycin in dermatology. Clin Dermatol 2003, 21(1):64-70.
527. Wilson P, Andrews JA, et al. Linezolid resistance in clinical isolates of Staphylococcus aureus. J Antimicrob Chemother 2003, 51:186-188.
528. Di Paolo A, Malacarne P, Guidotti E, et al. Pharmacological issues of linezolid: an updated critical review. Clin Pharmcokinet 2010, 49(7):439-447.
529. Zyvox(r) (linezolid injection, tablets, and oral suspension), Full Prescribing Information 2008, Pfizer, Inc, New York, NY.
530. Schweiger ES, Scheinfeld NS, Tischler HR, et al. Linezolid and quinupristin/dalfopristin: novel antibiotics for Gram-positive infections of the skin. J Drugs Dermatol 2003, 2(4):378-383.
531. Howden BP, Ward PB, et al. Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. Clin Infect Dis 2004, 38:521-528.
532. Wigen CL, Goetz MB Serotonin syndrome and linezolid. Clin Infect Dis 2002, 34:1651-1652.
533. Bernard L, Stern R, Lew D, et al. Serotonin syndrome after concomitant treatment with linezolid and citalopram. Clin Infect Dis 2003, 36:1197.
534. McKinley SH, Foroosan R Optic neuropathy associated with linezolid treatment. J Neuroophthalmol 2005, 25:18-21.
535. Briggs GG, Freeman RK, Yaffe SJ Linezolid. Drugs in Pregnancy and Lactation 2005, 922-923. Lippincott Williams & Wilkins, Philadelphia. 7th ed. G.G. Briggs, R.K. Freeman, S.J. Yaffe (Eds.).
536. Lorian VM, Fernandes F Synergistic activity of vancomycin-quinupristin/dalfopristin combination against Enterococcus faecium. J Antimicrob Chemother 1997, 39(Suppl A):63-66.
537. Bryson HM, Spencer CM Quinupristin-dalfopristin. Drugs 1996, 52:406-415.
538. Soltani M, Beighton D, Phipott-Howard J, et al. Mechanisms of resistance to quinupristin-dalfopristin among isolates of Enterococcus faecium from animals, raw meat and hospital patients in Western Europe. Antimicrob Agents Chemother 2000, 44:433-436.
539. Synercid(r) (quinupristin/dalfopristin for injection). Full Prescribing Information 2000, Aventis Pharmaceuticals Inc, Bridgewater, NJ.
540. Cubicin(r) (daptomycin for injection), Full Prescribing Information 2003, Cubist Pharmaceuticals, Lexington, MA.
541. Silverman JA, Pelmutter NG, Shaprio HM Correlation of daptomycin bactericidal activity and membrane depolarization in Staphylococcus aureus. Antimicrob Agents Chemother 2003, 47:2538-2544.
542. Zhanel G, Calic D, Schweizer F, et al. New lipopglycopeptides: A comparative review of dalbavancin, oritavancin and telavancin. Drugs 2010, 70(7):859-886.
543. Jones RN, Silwell MG, Sader HS, et al. Spectrum and potency of dalbavancin tested against 3322 Gram-positive cocci isolated in the United States Surveillance ProGram (2004), Diagnostic Microb. Infect Dis 2006, 54(2):149-153.
544. Zhanel GG, Trapp S, Gin AS, et al. Dalbavancin and telavancin: novel lipoglycopeptides for the treatment of Gram-positive infections. Expert Rev Anti Infect Ther 2008, 6(1):67-81.
545. Seltzer E, Dorr MB, Goldstein BP, et al. Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for the treatment of skin and soft tissue infections. Clin Infect Dis 2003, 37(10):1298-1303.
546. Jauregui LE, Babzadeh S, Seltzer E, et al. Randomized double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections. Clin Infect Dis 2005, 41(10):1407-1415.
547. Stryjewski ME, Chambers HF Skin and soft-tissue infections caused by community-acquired methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2008, 46(Suppl 5):S368-S377.
548. Stryjewski ME, Graham DR, Wilson SE, et al. Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by Gram-positive organisms. Clin Infect Dis 2008, 46(11):1683-1693.
549. Greenblatt DJ, Zhao Y, Duan SX, et al. Effects of oritavancin on human cytochromes P450 in vitro [poster no.A1-1284] 49th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 12-5, 2009, San Francisco, CA.